These results suggest that increased activation of the canonical pathway (leading to decreased levels of IκB-α and elevated NF-κB p65 DNA binding) may be due to events primarily affecting IKKβ in some MS patients. The gene discussed is NFKB1; the disease is myeloid sarcoma.